Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model.

Radiology

From the Human Phenome Institute (C.W., X.H., X.K., H.W.) and Institute of Science and Technology for Brain-inspired Intelligence (H.W.), Fudan University, Shanghai, China; Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China (Y.H., S.L., R.H.); Center of Portal Hypertension, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China (Y.H., Chuan Liu, X.Q.); Department of Radiology, Fifth Medical Center of Chinese People’s Liberation Army General Hospital, Beijing, China (Changchun Liu, W.A.); Department of Interventional Therapy, Beijing Shijitan Hospital, Beijing, China (F.L.); and Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China (Y.L.).

Published: April 2023

Background Currently, the hepatic venous pressure gradient (HVPG) remains the reference standard for diagnosis of clinically significant portal hypertension (CSPH) but is limited by its invasiveness and availability. Purpose To investigate a vascular geometric model for noninvasive diagnosis of CSPH (HVPG ≥10 mm Hg) in patients with liver cirrhosis for both contrast-enhanced CT and MRI. Materials and Methods In this retrospective study, consecutive patients with liver cirrhosis who underwent HVPG measurement from August 2016 to April 2019 were included. Patients without hepatic diseases were included and marked as non-CSPH to balance the ratio of CSPH 1:1. A variety of vascular parameters were extracted from the portal vein, hepatic vein, aorta, and inferior vena cava and then entered into a vascular geometric model for identification of CSPH. Diagnostic performance was assessed with the area under the receiver operating characteristic curve (AUC). Results The model was developed and tested with retrospective data from 250 patients with liver cirrhosis and 273 patients without clinical evidence of hepatic disease at contrast-enhanced CT examination, including 213 patients with CSPH (mean age, 49 years ± 12 [SD]; 138 women) and 310 patients without CSPH (mean age, 50 years ± 9; 177 women). For external validation, an MRI data set with 224 patients with cirrhosis (mean age, 49 years ± 10; 158 women) and a CT data set with 106 patients with cirrhosis (mean age, 53 years ± 12; 71 women) were analyzed. Significant reductions in mean whole-vessel volumes were observed in the portal vein (ranging from 36.9 cm ± 16.0 to 29.6 cm ± 11.1; < .05) and hepatic vein (ranging from 35.3 cm ± 21.5 to 22.4 cm ± 15.7; < .05) when CSPH occurred. Similarly, the mean whole-vessel lengths were shorter in patients with CSPH (portal vein: 1.7 m ± 1.2 vs 3.0 m ± 2.4, < .05; hepatic vein: 0.9 m ± 1.5 vs 1.8 m ± 1.5, < .05) than in those without CSPH. The proposed vascular model performed well in the internal test set (mean AUC, 0.90 ± 0.02) and external test sets (mean AUCs, 0.84 ± 0.12 and 0.87 ± 0.11). Conclusion A contrast-enhanced CT- and MRI-based vascular model was proposed with good diagnostic consistency for hepatic venous pressure gradient measurement. ClinicalTrials.gov registration nos. NCT03138915 and NCT03766880 © RSNA, 2023 See also the editorial by Roldán-Alzate and Reeder in this issue.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.221648DOI Listing

Publication Analysis

Top Keywords

age years
16
vascular model
12
patients liver
12
liver cirrhosis
12
portal vein
12
hepatic vein
12
patients csph
12
patients
10
csph
9
diagnosis clinically
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!